Selten Pharma, Inc. Receives Orphan Drug Designation From U.S. FDA for the Treatment of Pulmonary Arterial Hypertension

SARATOGA, Calif., March 18, 2015 -- (Healthcare Sales & Marketing Network) -- Selten Pharma, Inc., a privatively held biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare diseases, announced tod... Biopharmaceuticals, FDASelten Pharma, tacrolimus, pulmonary arterial hypertension

http://salesandmarketingnetwork.com/news_release.php?ID=2039631

Source: HSMN NewsFeed - March 18, 2015 Category: Pharmaceuticals Source Type: news